Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why AbbVie Is a Dividend Growth Stock That's Too Cheap to Ignore

By Greg Jones - Updated Feb 11, 2020 at 4:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Allergan deal will cement AbbVie’s position as a diversified pharmaceutical company with sustainable growth. It’s time for the shares to play catchup.

AbbVie ( ABBV 1.69% ) and Abbott Laboratories ( ABT 1.47% ) were born of the same parent but separated at birth. In 2013, Abbott Laboratories split into two companies, one primarily a medical device maker (which retained the parent's name) and the other a pharmaceutical company. That's where the similarities end, however. 

The siblings have since had very divergent paths -- at least in terms of their share prices. Whereas Abbott Labs has been steadily hitting new highs, AbbVie peaked in 2018 and has since fallen close to 30%.

For much of its history, AbbVie was the better horse to back than Abbott Labs. In the first five years after the spin-off, Abbvie rose over 200% while Abbott increased 78%. AbbVie's fortunes took a turn for the worse in 2018, and since then, relative stock performance has reversed with Abbott rising close to 50%.

Hand holding blue marker with drawing of a line sloping upward and the word "dividends" written above the line

Image source: Getty Images.

A one trick pony?

The source of AbbVie's initial outperformance, as well as its ensuing decline, relates to its mainstay drug Humira, which treats various autoimmune diseases and also happens to be the world's best-selling drug. The success of Humira has been staggering. In the six years since AbbVie's inception, Humira's sales doubled from $10.6 billion in 2013 to $19.9 billion in 2018. With the drug accounting for close to 60% of sales and a higher portion of profits, AbbVie's fortunes have been inextricably tied to Humira's.

It's not surprising then that AbbVie's share price peaked in anticipation of the expiration of the European Union (EU) patent on Humira, which took place on Oct. 16, 2018. Three biosimilars of Humira launched immediately after the patent expired: Novartis' Hyrimoz, Amgen's Amgevita and Biogen's Imraldi. Although the U.S. still accounts for the vast majority of Humira's sales, the patent expiration put at risk the $6 billion that Humira generates internationally. 

These risks have been borne out. In AbbVie's third-quarter results, Humira's international sales fell more than 33%. While US sales continued to grow, the impact of the fall in international revenue was enough to drag Humira's overall sales down nearly 4%. Extrapolating the impact of the EU patent expiration, it is not surprising then that investors worry about what will happen after 2023 when Humira's US patent expires.

Hedging its bets

AbbVie has not been sitting idly by waiting for the Humira patent expiration story to play out. The company has been actively developing a strong pipeline of next-generation immunology and oncology drugs, such as Imbruvica and Venclexta to treat blood cancer and Skyrizi to treat psoriasis. 

AbbVie's pipeline includes 60 compounds or indications in clinical development, including 30 which are in mid- to late-stage development. Indeed, the company's most recent results reflect the success of these efforts -- Q3 worldwide net revenues rose 3% to $8.5 billion despite the decline in Humira's sales and AbbVie raised its 2019 full-year adjusted earnings per share (EPS) guidance.

To cement its efforts to diversify away from Humira, AbbVie went one step further. In June, the company announced that it would acquire Allergan ( AGN ), a specialty-drug manufacturer known for blockbuster drugs such as Botox and Restasis, for $63 billion.

The acquisition brings a number of benefits. With $16 billion in annual revenue in mostly unrelated therapeutic markets, Allergan's addition will further wean AbbVie off of dependence on Humira's franchise. The deal would be immediately accretive to earnings, contributing 10% to adjusted EPS in the first year with peak accretion in excess of 20%. The acquisition would also create immediate scale, with the combined entity ranking fourth in overall revenues and third in operating cash flow. 

Operating cash flow, in addition to helping pay off the additional debt incurred in the acquisition, should also facilitate further dividend increases. In the third quarter, AbbVie continued its impressive streak of dividend hikes by announcing a 10.3% increase, boosting its accumulated dividend increase since separating from Abbott Labs to 195%.

Too cheap to ignore

At a price-to-earnings ratio of less than nine times forward earnings, AbbVie looks like a bargain compared to the market multiple of over 17 times expected earnings. It's high time for AbbVie to regain its luster as the better-performing sibling. In the meantime, AbbVie remains a great dividend stock with solid growth prospects that's too cheap for investors to ignore.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
$118.85 (1.69%) $1.98
Abbott Laboratories Stock Quote
Abbott Laboratories
$130.27 (1.47%) $1.89
Allergan plc Stock Quote
Allergan plc
Novartis AG Stock Quote
Novartis AG
$80.00 (0.06%) $0.05
Biogen Inc. Stock Quote
Biogen Inc.
$223.92 (-2.01%) $-4.60
Amgen Inc. Stock Quote
Amgen Inc.
$202.44 (0.63%) $1.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.